Changes in health in Belgium, 1990-2016 : a benchmarking analysis based on the global burden of disease 2016 study by Maertens de Noordhout, Charline et al.
RESEARCH ARTICLE Open Access
Changes in health in Belgium, 1990–2016: a
benchmarking analysis based on the global
burden of disease 2016 study
C. Maertens de Noordhout1*, H. Van Oyen2,3, N. Speybroeck1 and B. Devleesschauwer2,4
Abstract
Background: Despite increasing of the Belgian health expenditures, several indicators related to population health
showed poor results. The objectives of this study were to perform an in-depth analysis of the secular trend of
Belgian health status using the Global Burden of Disease (GBD) 2016 study results for Belgium, and to compare
these results with other European countries.
Methods: We collected results of the Global Burden of Disease 2016 study through the GBD results and
visualization tools. We benchmarked Belgian GBD results with the other initial members of the European Union
(EU15).
Results: Belgium performed significantly better in 2016 than in 1990 in terms of age-standardized (AS) Year of Life
Lost (YLL) rates but not significantly different in terms of AS Year Lived with Disability (YLD) and Disability-Adjusted
Life Year (DALY) rates. The contribution of AS YLDs to total of AS DALYs increased from 1990 (42%) to 2016 (54%).
Although AS YLD and DALY rates did not seem to differ between Belgium and the EU15 from 1990 to 2016, the
ranking of Belgium among the EU15 in terms of AS DALY and YLL rates was worse in 2016 than in 1990. Belgium
had significantly higher AS YLL rates for lower respiratory infections (B: 264 AS YLLs [95% uncertainty interval [UI]
231–301] per 100,000; EU15: 188 AS YLLs [95%UI 168–212] per 100,000), chronic obstructive pulmonary disease (B:
368 AS YLLs [95%UI 331–407] per 100,000; EU15: 285 AS YLLs [95%UI 258–316] per 100,000) and tracheal, bronchus,
and lung cancer (B: 785 AS YLLs [95%UI 699–879] per 100,000; EU15: 613 AS YLLs [95%UI 556–674] per 100,000).
Conclusion: Belgium’s ranking among the EU15 in terms of AS YLL and DALY rates decreased from 1990 to 2016.
Significant health gains appear possible by acting on risk factors directly linked to a significant part of the Belgian
burden of diseases, i.e., alcohol and tobacco consumption, and high body mass index. National burden of disease
estimates can help defining Belgian health targets and are necessary as external validity of GBD results is not always
guaranteed.
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Background
The Belgian health system is characterized by a compul-
sory national health insurance which covers almost the
entire population, a free choice of physician, and pre-
dominantly fee-for-service payment. The system aims to
ensure solidarity between rich and poor, and between
healthy and sick people. The mandatory health insurance
covers more than 8000 services. The Belgian health sys-
tem is mainly financed by progressive direct taxation,
proportional social security contributions related to in-
come and alternative financing related to the consump-
tion of goods and services [1].
In 2015, the Belgian Health System Performance As-
sessment report highlighted the satisfaction of the Bel-
gian population with regards to their health system2 and
according to the Euro Health Consumer Index 2016,
which judges the satisfaction of the population regarding
accessibility and quality of national health care, Belgium
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ranked fourth within EU15, i.e. after the Netherlands,
Switzerland and Norway [2].
Since 1990, the Belgian federal and regional governments
introduced multiple measures for tobacco control [3], can-
cer screening [4, 5], road injuries prevention [6, 7], healthier
nutritional habits and physical activities [8] improved air
quality [9] and care accessibility [10]. However, the Belgian
Health System Performance Assessment report demon-
strated that Belgium could do better in terms of health re-
sults. Several indicators of health promotion and lifestyle
showed poor results and some of the mental health and
mental health care indicators were alarming [2]. In addition,
the Organisation for Economic Co-operation and Develop-
ment (OECD) highlighted emerging issues related to in-
equalities in health and access to care, low investment in
prevention, increase in some risk factors and waste in clin-
ical care [11]. Health interview survey also highlighted that
screening remained scattered and at low level in 2000 [12].
Despite these disappointing health results, health ex-
penditure increased as a percentage of gross domestic
product from 7.1% in 1990, to 10.4% in 2016, making
Belgium’s health expenditure the fifth highest among all
European countries in terms of percentage of gross do-
mestic product [13]. Indeed, most of the costs in health
seem to be linked to the way care is practiced in Belgium
and the costs linked to investments in promotion and
prevention actions and to ensure more equitable access
are almost negligible [12].
In a context of pressure on social security as well as
epidemiological and demographic changes, it seems cru-
cial to focus effort on diseases and risk factors that cause
the greatest burden on public health and to learn from
the past and from other countries to invest better.
Therefore, the objectives of this study were: 1) to per-
form an in-depth analysis of the Belgian health status
changes between 1990 and 2016 using the Global Bur-
den of Disease (GBD) 2016 study results for Belgium,
and 2) to compare the Belgian health status with other
European countries in 2016.
Methods
Overview
We collected results of the GBD 2016 study through the
GBD results [14] and visualization tools [15]. Detailed
information about data, approaches, statistical model-
ling, and metrics for the GBD 2016 study have been re-
ported previously [16–21].
The GBD 2016 study used several metrics to quantify
health impact of specific disease and injury causes – i.e.,
incidence, prevalence, mortality, Years of Life Lost due
to premature mortality (YLLs), Years Lived with Disabil-
ity (YLDs), Disability-Adjusted Life Years (DALYs) and
Health-Adjusted Life Expectancy (HALE). The GBD
2016 study included also the Socio-Demographic Index
(SDI), a summary measure of a geography’s
socio-demographic development. SDI is based on aver-
age income per person, educational attainment, and total
fertility rate. In this study we focused on mortality, YLLs,
incidence, prevalence, YLDs and DALYs.
YLLs are expressing years of life lost and are com-
puted by multiplying the number of deaths for a specific
cause in each age-group by a reference life expectancy at
that age. The life expectancy at birth in the GBD 2016
reference life table is 86 years for both sexes [22]. YLDs
are calculated by multiplying the prevalence of sequelae
by their disability weight (DW). DALYs are the sum of
YLLs and YLDs [23, 24].
Deaths, YLLs, YLDs, and DALYs attributable to 84 risk
factors or clusters of risk factors were also assessed in
the GBD 2016 study [17]. In this study we investigated
estimates of DALYs for all risks.
Although a complete set of age-specific, sex-specific,
cause-specific, and geography-specific burden is available
for the years 1990, 1995, 2000, 2005, 2010 and 2016 in
the GBD estimations, we focused on the difference be-
tween 1990 and 2016, together with more detailed re-
sults for 2016.
Benchmarking
We benchmarked Belgian GBD results with the other
initial members of the European Union (EU15) – i.e.,
Austria, Denmark, Finland, France, Germany, Greece,
Ireland, Italy, Luxembourg, Netherlands, Portugal,
Spain, Sweden and the United Kingdom. Benchmark-
ing with the other EU15 countries is most relevant to
Belgian policy-makers; however, Belgium could easily
be compared with (European) countries not included
in our analysis using the GBD tools mentioned above.
For diseases, injuries or risk factors, we ranked coun-
tries in 1990 and 2016 according to their
age-standardized YLD, YLL, and DALY rates.
Age-standardized rates in GBD are estimated using
the GBD world population age standard. Briefly, they
used the age-specific proportional distributions of all
national locations from the World Population Pros-
pects 2012 revision for all years from 2010 to 2035
and generated a standard population structure by
taking the non-weighted mean across all the
country-years [18]. Age-standardized rates allow
comparing health outcomes across countries and are
consequently often used for benchmarking studies
[25, 26]. All rates presented in this manuscript there-
fore represent age-standardized rates, unless specified
otherwise.
We evaluated if Belgian results were significantly dif-
ferent between 1990 and 2016 by visually determining
whether the 95% uncertainty intervals (UIs) overlapped.
We also estimated if Belgian performances were
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significantly different from the EU15 estimates from
GBD 2016 by comparing the 95% UIs and ranked EU15
countries according to YLLs, YLDs and DALYs in 2016.
Results
Mortality and years of life lost
Life expectancy (LE) at birth in the Belgium increased by
4.1 years (95% UI 3.5–4.9) for females and by 5.8 years
(95% UI 5.1–6.4) for males from 1990 to 2016 (Fig. 1).
Belgium did not perform differently than the EU15 aver-
age increase in LE at birth for females (+ 4.7 [95%UI
4.2–5.2]) and for males (+ 6.4 [95%UI 5.9–7.0]), nor for
the EU15 average life expectancy at birth for females
(Belgium: 83.4 years [95%UI 82.3–84.5] - EU15:
83.9 years [95%UI 83.1–84.8]) and males (Belgium:
78.4 years [95%UI 77.2–79.5] - EU15: 79.1 years [95%UI
78.2–80.1]) in 2016.
For women, Belgium ranked tenth in terms of mortal-
ity rate (MR) and did not perform significantly different
than the EU15 female average in terms of MR in 2016
(Belgium: 408 [95% UI: 359–455] per 100,000; EU15:
389 [95% UI: 352–426] per 100,000). For men, Belgium
ranked fourteenth and did not perform significantly dif-
ferent than the EU15 male average in terms of mortality
rate (MR) in 2016 (Belgium: 642 [95% UI: 580–714] per
100,000; EU15: 605 [95% UI: 555–659] per 100,000).
In males, the major causes of mortality in Belgium in
2016 were ischemic heart disease (161 deaths [95% UI
143–180] per 100,000), lung, tracheal and bronchus can-
cer (95 deaths [95% UI 83–109] per 100,000) and Alz-
heimer’s disease (69 deaths [95% UI 56–84] per
100,000). Alzheimer’s disease (152 deaths [95% UI 123–
183] per 100,000), ischemic heart disease (148 deaths
[95% UI 131–168] per 100,000) and chronic obstructive
pulmonary disease (COPD) (47 deaths [95% UI 41–54]
per 100,000) were the leading causes of mortality in fe-
males (Additional file 1).
Deaths leading to YLLs, caused 15,115 YLLs [95% UI
14,649–15,566] per 100,000 in 1990 and 9221 YLLs
[95% UI 8422–10,020] per 100,000 in Belgium in 2016.
There was therefore a significant decrease of YLLs from
1990 to 2016 in Belgium.
The top three causes of YLL rates changed between
1990 and 2016 in females i.e., lung, tracheal and bron-
chus cancer was the third cause of YLL rates in 2016
but only the eighth in 1990. The major causes of YLL
rates in females in 2016 in Belgium were ischemic heart
disease (597 YLLs [95% UI 517–684] per 100,000),
breast cancer (561 YLLs [95% 472–649] per 100,000),
and tracheal, bronchus and lung cancer (440 YLLs [95%
372–511] per 100,000).
In males, although their relative contribution to total
YLLs decreased drastically, the top three causes of YLL
rates did not change between 1990 and 2016 – i.e., is-
chemic heart disease (1417 YLLs [95% UI 1246–1603]
per 100,000), tracheal, bronchus and lung cancer (1178
YLLs [95% UI 1020–1350] per 100,000) and self-harm
by other specified means (870 YLLs [95% UI 711–1173]
per 100,000) were still in the top of the ranking.
The top three causes of YLLs in females and males
were consistent across all EU15 countries. (Fig. 2).
Although Belgium did not perform significantly worse
than the EU15 countries in terms of age-standardized
YLL rates in 2016 (Belgium: 9221 YLLs [95%UI 8422–
10,020] per 100,000 – EU15: 8531 YLLs [95%UI 7939–
9166] per 100,000), Belgium fell drastically in the EU15
ranking between 1990 and 2016. Indeed, Belgium ranked
14th in terms of YLLs per 100,000 in 2016, i.e., 7 places
less than in 1990. Spain had the lowest YLLs (7314 YLLs
[95%UI 6967–7681] per 100,000) while UK was in last
position (9222 YLLs [95%UI 9084–9372] per 100,000) in
2016 (Fig. 3).
Compared to the EU15, Belgium had significantly lower
YLLs for stomach cancer (Belgium: 105 YLLs [95%UI 97–
Fig. 1 Difference in life expectancy at birth by sex, 1990–2016, EU15
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112] per 100,000; EU15: 132 YLLs [95%UI 120–145] per
100,000) and diabetes mellitus (Belgium: 108 YLLs
[95%UI 96–120] per 100,000; EU15: 131 YLLs [95%UI
122–150] per 100,000). Conversely, Belgium had signifi-
cantly higher YLLs for lower respiratory infections
(Belgium: 264 YLLs [95%UI 231–301] per 100,000; EU15:
188 YLLs [95%UI 168–212] per 100,000), for chronic ob-
structive pulmonary disease (Belgium: 368 YLLs [95%UI
331–407] per 100,000; EU15: 285 YLLs [95%UI 258–316]
per 100,000) and tracheal, bronchus, and lung cancer
(Belgium: 785 YLLs [95%UI 699–879] per 100,000; EU15:
613 YLLs [95%UI 556–674] per 100,000) (Fig. 4).
Fig. 2 Ranking (decreasing) of causes according to age-standardized Years of Life Lost rate, by sex, EU15, 2016. Other cardiovascular diseases =
cardiovascular and circulatory diseases different than rheumatic heart disease, ischemic heart disease, cerebrovascular disease, hypertensive heart
disease cardiomyopathy and myocarditis, atrial fibrillation and flutter, aortic aneurysm, peripheral vascular disease and endocarditis
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Disability
Disabilities resulted in 10,833 [95% UI 8060–14,038]
YLDs per 100,000 in 1990 and 10,786 [95% UI 8005–
13,981] YLDs per 100,000 in 2016 (Additional file 1).
There was no significant difference of YLDs rates be-
tween 1990 and 2016 in Belgium.
The major causes of YLDs in 2016 in males were low back
pain (1127 YLDs [95% UI 789–1516] per 100,000), migraine
(523 YLDs [95% UI 334–736] per 100,000) and falls (450
YLDs [95% UI 304–631] per 100,000) (Additional file 1). For
all age-groups in males, the contributions of major depres-
sion (+ 24%), benign prostatic hyperplasia (+ 18%), and falls
(+ 12%), to total YLDs rates rose from 1990 to 2016.
In females low back pain (1403 YLDs [95% UI 984–
1863] per 100,000), migraine (1042 YLDs [95% UI 662–
1464] per 100,000) and major depression (702 YLDs
[95% UI 479–962] per 100,000) caused most of the YLDs
in 2016 (Additional file 1). For all age-groups in females,
the contributions of major depression (+ 22%) and falls
(+ 18%) rose to total YLDs rates from 1990 to 2016.
In 2016, females contributed slightly more YLDs
(11,515 YLD [95% UI 8584–14,952] per 100,000) than
males (10,070 YLD [95% UI 7441–13,034] per 100,000).
For both men and women in 2016, the group over
80 years showed the highest YLD rate (105,949 YLD
[95% UI 80,256–134,106] per 100,000), followed by the
75–79 years (24,813 YLD [95% UI 18,777–31,605] per
100,000) and 70–74 years (21,775 YLD [95% UI 16,320–
28,189] per 100,000) groups. The groups of < 1 year
(3424 YLD [95% UI 2384–4751] per 100,000) had the
lowest burden in terms of YLDs in both sexes in 2016.
Compared to 1990, Belgium lost a place in 2016 and is
the median of the EU countries, i.e. 8th in terms of
YLDs rates. However, no significant difference was ob-
served of the overall YLDs rates in 1990 and 2016 be-
tween Belgium and EU15 (Additional file 1) and 2016
cause specific YLD’s (Fig. 4).
Disability-adjusted life years
All causes of diseases resulted in 25,948 age-
standardized Disability-Adjusted Life Years (DALYs)
[95% UI 23,160–29,223] per 100,000 in 1990 and 20,027
DALYs [95% UI 17,333–22,747] per 100,000 in 2016.
There was no significant difference of DALY rates be-
tween 1990 and 2016 in Belgium. In 1990, 42% of the
total DALYs was caused by YLDs and in 2016, 54% of
the total DALYs was caused by YLDs.
Despite an impressive decrease of DALYs between 1990
and 2016 (− 2380 DALYs per 100,000), ischemic heart dis-
ease remained the number one cause of DALYs in males in
2016 (8.5% [95% 7.6–9.5 UI] of total DALYs). Lung, tra-
cheal and bronchus cancer (6.4% [95% 5.5–7.3 UI] of total
DALYs) and low back pain (4.8% [95% 3.7–5.9 UI] of total
DALYs) were second and third major causes of DALYs in
males in 2016 (Additional file 1). DALYs per 100,000
caused by major depressive disorder (+ 77 DALYs per
100,000), alcohol use disorders (+ 44 DALYs per 100,000)
and falls (+ 23 DALYs per 100,000) increased between 1990
and 2016 in males in Belgium (Table 1).
Fig. 3 Ranking (ascending) of EU15 countries according to age-
standardised Years of life Lost (YLLs) per 100,000, 1990–2016
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In females, DALYs caused by major depressive dis-
order increased drastically between 1990 and 2016
(+ 127 DALYs per 100,000) and appeared as the third
cause of DALYs in 2016. The major causes of DALYs in
females in 2016 were low back pain (6.7% [95% 5.4–8.0
UI] of total DALYs) and migraine (5.7% [95% 4.9–6.6
UI] of total DALYs) (Table 2). DALYs caused by falls
(+ 53 DALYs per 100,000) also increased between 1990
and 2016 in females in Belgium.
Low back pain and ischemic heart disease were the
diseases that caused most of the DALYs in females and
males respectively in all European countries in 2016.
For both men and women in 2016, the youngest age
group of infants aged 0–6 days showed the highest
DALY rate (665,481 DALYs [95% UI 555,762–793,147]
per 100,000), followed by the 80+ years (471,865 DALYs
[95% UI 432,866 –512,650] per 100,000) and 7–27 days
(79,437 DALYs [95% UI 67,225–93,449] per 100,000)
groups (Fig. 5).
Although we did not observe significant differences of
DALYs rates between Belgium and the EU15 in 1990
(Belgium: 25,498 DALYs [95% UI 23,160–29,223] per
100,000; EU15: 26,027 DALYs [95% UI: 23,154–29,269]
per 100,000) and in 2016 (Belgium: 20,006 DALYs [95%
UI 17,108–23,233] per 100,000; EU15: 19,249 DALYs
[95% UI: 16,374–22,432] per 100,000), the ranking of
Belgium among the EU15 in terms of DALYs in both
sexes was worse in 2016 than in 1990. Indeed Belgium
moved from 7th to 14th place in terms of DALYs per
100,000 and for all age groups, except for 0–6 days,
7–27 days and 5–14 years groups, ranking became worse
(Fig. 6).
Finally, Belgium ranked twelfth in terms of difference
of DALYs per 100,000 from 1990 to 2016, which means
that despite improving of health between 1990 and 2016,
Belgium did worse than most of the EU15 countries. In
Belgium most of the difference of DALYs rate from 1990
to 2016 was linked to a reduction in YLLs rate (99%)
(Table 3).
Risk factors
In 1990, the considered risk factors accounted for
7195 DALYs [95% UI: 6640–7818] per 100,000 in fe-
males and 14,853 DALYs [95% UI: 13,931–15,872]
per 100,000 in males. In 2016, the number of DALYs
linked to risk factors decreased in both females
(5114 DALYs [95% UI: 4467–5796] per 100,000) and
males (8975 DALYs [95% UI: 7948–10,179] per
100,000). Proportions of DALYs attributed to risk
factors also decreased between 1990 and 2016 in fe-
males (− 4% of total DALYs) and males (− 8% of total
DALYs).
Fig. 4 Top 25 causes of age-standardised (AS) Years of life lost (YLLs) per 100,000, 2016, Belgium. Red dots represent EU15 average AS YLLs per
100,000 in 2016. Other neoplasms = Neoplasms different than lip and oral cavity cancer, nasopharynx cancer, oesophageal cancer, stomach
cancer, colon and rectum cancer, liver cancer, gallbladder and biliary tract cancer, pancreatic cancer, larynx cancer, tracheal, bronchus, and lung
cancer, malignant skin melanoma, non-melanoma skin cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, prostate cancer,
testicular cancer, kidney cancer, bladder cancer, brain and nervous system cancer, thyroid cancer, mesothelioma, Hodgkin lymphoma, multiple
myeloma and leukaemia
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In males, the leading risk factors of age-standardized
DALYs in Belgium in 2016 were smoking (14% of total
DALYs), alcohol use (9% of total DALYs) and high sys-
tolic blood pressure (8% of total DALYs) and risk factors
resulted mainly in cardiovascular diseases and neo-
plasms (Fig. 7).
In females, smoking (7% of total DALYs), high systolic
blood pressure (6% of total DALYs) and high body mass
index (6% of total DALYs) were the major risk factors of
DALYs in 2016 and caused mainly cardiovascular diseases,
neoplasms and diabetes (Fig. 8). Additional results on risk
factors in Belgium are available in the Additional file 1.
Discussion
Overall the health status of the Belgian population im-
proved between 1990 and 2016 but to a lesser extent
compared to the other EU15 countries. Belgium ranked
worse in 2016 than in 1990 among the EU15 countries.
This study further highlighted some important changes
in health in Belgium between 1990 and 2016.
First, LE at birth increased in Belgium between 1990
and 2016 (4.1 years (95% UI 3.5–4.9) for females and
5.8 years (95% UI 5.1–6.4) for males) and is not signifi-
cantly below the average EU15. We observed the same
pattern for death as for LE at birth, i.e. a significant im-
provement between 1990 and 2016 in Belgium and an
average MR not different than the EU average in 2016.
Alzheimer’s disease and ischemic heart disease are a
major cause of death in both sexes in Belgium.
Second, there was a significant decrease of YLLs
from 1990 to 2016 in Belgium. Ischemic heart disease
(IHD), breast cancer and lung, tracheal and bronchus
cancer were the leading causes of premature mortality
in females in Belgium in 2016 and IHD, lung, tracheal
and bronchus cancer and self-harm were the main
causes of the premature deaths in males. The Belgian
Health Care Knowledge Center also published alarm-
ing conclusions for mental health care and revealed
that the Belgian suicide rate (18.3 per 100,000 popula-
tion) was considerably higher than in other European
countries (10.6 for EU15 countries) [2]. Bossuyt and
colleagues also reported that between 1993 and 1995
and 2000–2001, the incidence of suicide increased
among men in Belgium [27] and Vancayseele and
Table 1 Age-standardized Disability-Adjusted Life Years per 100,000 by cause, males, 1990 and 2016, Belgium
Belgium, 1990 Belgium, 2016
Causes DALY
rank
DALY a
rate
LB 95%
UI
UB 95%
UI
DALY
rank
DALYa
rate
LB 95%
UI
UB 95%
UI
Absolute DALYs
changesa
Ischemic heart disease 1 3936 3716 4159 1 1556 1384 1748 −2380
Tracheal, bronchus, and lung cancer 2 2140 1987 2296 2 1195 1038 1367 − 945
Low back pain 3 1143 795 1512 3 1127 789 1516 −17
Self-harm by other specified means 5 954 826 1381 4 879 720 1186 −75
Chronic obstructive pulmonary
disease
4 1115 1032 1204 5 666 578 755 −449
Falls 9 617 483 789 6 640 481 827 23
Migraine 11 527 337 753 7 523 334 736 −4
Alzheimer disease and other
dementias
13 491 410 587 8 460 382 558 −31
Age-related and other hearing loss 18 434 296 632 9 425 288 625 −9
Major depressive disorder 23 334 225 456 10 411 281 566 77
Neck pain 20 406 270 578 11 407 273 583 0
Diabetes mellitus 16 446 361 547 12 392 304 496 −53
Colon and rectum cancer 10 535 495 580 13 381 326 442 −154
Other cardiovascular and circulatory
diseases
17 442 362 539 14 374 314 457 −67
Lower respiratory infections 19 429 387 470 15 362 304 428 −67
Anxiety disorders 21 352 244 476 16 353 245 479 0
Hemorrhagic stroke 8 648 598 701 17 338 292 388 − 311
Motor vehicle road injuries 6 902 755 998 18 330 274 414 − 573
Alcohol use disorders 25 282 224 359 19 327 263 401 44
Ischemic stroke 7 723 660 792 20 325 277 374 − 398
aage-standardized DALY per 100,000
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Table 2 Age-standardized Disability-Adjusted Life Years per 100,000 by cause, females, 1990 and 2016, Belgium
Belgium, 1990 Belgium, 2016
Causes DALY
rank
DALY a
rate
LB 95%
UI
UB 95%
UI
DALY
rank
DALYa
rate
LB 95%
UI
UB 95%
UI
Absolute DALYs
changesa
Low back pain 2 1423 997 1888 1 1403 984 1863 −19
Migraine 3 1048 667 1486 2 1042 662 1464 −6
Major depressive disorder 7 575 392 787 3 702 479 962 127
Ischemic heart disease 1 1781 1684 1883 4 680 598 770 − 1101
Breast cancer 4 920 862 989 5 610 521 699 − 310
Anxiety disorders 5 584 401 799 6 582 402 799 −2
Neck pain 8 563 379 799 7 563 380 803 0
Alzheimer disease and other
dementias
6 577 493 676 8 526 434 636 −51
Falls 11 460 349 600 9 513 386 670 53
Tracheal, bronchus, and lung
cancer
23 299 274 325 10 447 378 518 148
Chronic obstructive pulmonary
disease
16 365 336 395 11 353 309 399 −12
Age-related and other hearing loss 17 352 238 512 12 348 237 508 −4
Self-harm by other specified means 13 419 388 450 13 335 282 392 −84
Acne vulgaris 21 314 208 453 14 332 221 482 18
Other cardiovascular and circulatory
diseases
14 401 325 488 15 323 265 390 −78
Other musculoskeletal disorders 22 299 200 424 16 319 218 453 20
Diabetes mellitus 12 431 356 521 17 300 229 385 −131
Bipolar disorder 24 255 130 442 18 255 127 450 0
Hemorrhagic stroke 10 512 474 554 19 255 219 292 −257
Ischemic stroke 9 541 490 595 20 248 208 291 − 293
aage-standardized DALY per 100,000
Fig. 5 Disability-Adjusted Life Years per 100,000 and 95% UI by age-group, 2016, Belgium
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colleagues reported the highest rates of suicide in
Flanders among adolescents and young adults and in
2008, i.e. related to the beginning of the economic
crisis [28].
Third, even if Belgium did not seem to perform signifi-
cantly worse than the EU15 in terms of YLLs in 2016,
we observed that Belgium fell drastically in the EU15
ranking from 1990 (7th rank) to 2016 (14th rank) and
that Belgium had significantly higher YLLs rates than
EU15 for some specific causes as lower respiratory infec-
tions, chronic obstructive pulmonary disease and tra-
cheal, bronchus, and lung cancer. This result has also
been supported by the Belgian Health Care Knowledge
Center that highlighted that premature death was rela-
tively high in Belgium in 2015 and that it was
particularly the case for causes of death preventable
through public policies (for instance deaths from lung
cancer) [2].
Fourth, YLDs were mainly driven by low back pain,
migraine, major depressive disorders and falls in 2016 in
Belgium. There was no major change in YLDs rates in
Belgium between 1990 and 2016 for both males and fe-
males and we did not observe significant difference of
YLDs rates between Belgium and EU15.
Fifth, we did not observe major differences in DALY
rates between 1990 and 2016 and the proportion of
the burden attributed to YLDs increased from 1990
to 2016 in Belgium. In other words, most of the bur-
den of diseases in Belgium in 2016 is caused by years
lived with disabilities. This could be explained by
Fig. 6 Ranking (ascending) of Belgium, age-standardized Disability-Adjusted Life Years per 100,000 among EU15, both sexes, 1990 and 2016
Table 3 Age-standardized Disability-Adjusted Life Years per 100,000, difference between 1990 and 2016, EU15
Country Difference DALYs 90–16 per
100.000
LB
95%UI
UB 95%
UI
% YLLs in Difference DALYs 90–
16
% YLDs in Difference DALYs 90–
16
Portugal − 9131 −9221 − 9232 96% 4%
Luxembourg − 8813 − 8749 − 8956 94% 6%
Finland − 8345 − 8212 − 8494 95% 5%
Ireland − 7610 − 7569 − 7548 98% 2%
Austria − 7210 − 7188 − 7145 97% 3%
Germany − 6962 − 7020 − 6780 96% 4%
Spain − 6942 − 6880 − 7212 95% 5%
Denmark − 6939 − 6903 − 6940 101% −1%
Italy − 6433 − 6400 − 6580 94% 6%
United
Kingdom
− 6248 − 6198 − 6328 96% 4%
France − 5957 − 5974 − 6005 95% 5%
Belgium − 5942 − 6052 − 5990 99% 1%
Netherlands − 5434 − 5631 − 5419 97% 3%
Sweden − 4962 − 4992 − 4939 99% 1%
Greece − 4742 − 4720 − 4987 96% 4%
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increasing of life expectancy and of number of people
living with comorbidities. We also highlighted an im-
portant increasing of DALYs linked to major depres-
sive disorders in both sexes in Belgium from 1990 to
2016 and that the ranking of Belgium among the
EU15 in terms of DALYs in both sexes was drastic-
ally worse in 2016 (14th rank) than in 1990 (7th
rank).
Finally, although we observed that DALYs caused by risk
factors decreased significantly in Belgium from 1990 to
2016, we also highlighted that smoking, high blood pres-
sure, high body mass index and alcohol use were still the
major risk factors of DALYs in Belgium in 2016. OECD
also highlighted that alcohol consumption was a major
risk factor of death and classified Belgium 2nd highest rate
of alcohol consumption across the EU28 [11]. Van Oyen
Fig. 7 Risk factors of age-standardized Disability-Adjusted Life Years per 100,000, males, 2016, Belgium
Fig. 8 Risk factors of age-standardized Disability-Adjusted Life Years per 100,000, females, 2016, Belgium
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and colleagues concluded that smoking kills and shortens
both life without and life with disability in Belgium [29] and
Yokota and colleagues showed an increasing trend of the
disability prevalence and different contributors to the dis-
ability burden across smoking categories in Belgium [30].
Although this is the first in-depth analysis of the Bel-
gian GBD results, these results have to be interpreted
carefully and cannot replace a national burden of disease
study because they suffer from all limitations of GBD
2016 estimates already discussed widely and in detail
elsewhere [16–19]. We summarize the relevant limita-
tions for Belgium and EU15 countries focusing on data
sources and model used.
First, in the GBD 2016 study there were no data for
some sequelae and for some or even many countries
making estimates for a country and between countries
over time challenging. For Belgium, 520 data sources
were reported in Global Health Data exchange (GHDx)
and only one referred to the year 2016. In other words,
GBD 2016 estimates for Belgium were largely based on
data from previous years or from other countries, even
non-European countries. Among the EU15 countries,
UK (n = 2998), Italy (n = 1754), Sweden (n = 1649),
France (n=1182) and the Netherlands (n = 1090) had
most of the data sources reported in GHDx. Although
Belgium is probably behind in terms of health data col-
lection compared to other EU15 countries, some avail-
able data sources as Belgian Cancer Registry or Belgian
Diabetes Registry were not used by the Institute for
Health Metrics and Evaluation (IHME) in the GBD 2016
estimates. Presenting results for the time window 1990
to 2016 could mask very recent changes, e.g. in the last
ten years; however, we decided to present results for this
time window because, as demonstrated above, the rele-
vance of GBD’s estimates for the most recent years is
not always guaranteed. Changes in data quality over time
can also occur and can have an impact on the GBD esti-
mates, even if all estimates are generated within a single
model. As GBD 2016 Belgian results are based on data
from other countries and complex modeling, it is im-
portant to not solely relying on GBD estimates, to in-
crease investments in national health monitoring and to
generate national health status and burden of disease es-
timates [25].
Second, as detailed elsewhere [26, 31], Bayesian
models were used to estimate health metrics of condi-
tions in each country, age, sex and year. The nature of
this estimation process means that, without data or
powerful covariates, estimated variance might be smaller
than the real variance. Results for Belgium have been in-
formed by many available data sources such as vital
registration data, surveillance report or studies on spe-
cific diseases. UIs provide some information about the
extent of available information for Belgium.
It is also noteworthy that there are international agencies
that publish EU15 health status reports such as OECD,
European Commission, World Health Organization
(WHO), and the WHO European Regional Office. The main
advantage of the IHME initiative is that it generates intern-
ally consistent estimates, thus allowing for comparisons
across countries. However, external validity is not always
guaranteed, as evidenced by the differences between differ-
ent reports.
Finally, comparing overlapping UIs is not a very robust
method to estimate differences of health status across
countries and year. Indeed, when UIs do not overlap, it
is safe to conclude that the differences are significantly
different; however, when UIs do overlap, the difference
can still be statistically significant. In other words, it
means that there may still be differences of health status
between EU15 countries even if UIs overlap. However as
GBD results are based on simulation, comparing UIs is
the only possible method.
Between 1990 and 2016, several health policies
have been initiated in Belgium, for instance, the
introduction in 1999 of a Global Medical Dossier for
patients to strengthen the role of primary care, the
extension of preferential reimbursements to all per-
sons under a fixed income limit, the introduction in
2007 of reimbursements for analgesic drugs and ban-
dages, the launch in 2008 of a cancer plan and a na-
tional action plan for alcohol, the introduction in
2009 of the pathway for diabetes follow-up and
chronic renal failure or prohibition in 2011 of smok-
ing in closed public places. Although these measures
may have contributed to an improvement of the
health of the Belgian population, we also observed
that Belgium performed less well than other EU15
countries.
Multiple other factors than demographic changes and
policies may have contributed to the fact that the aver-
age Belgian health status became worse than other EU15
countries, for instance health competencies distributed
among different levels of power or the education system.
However, Belgian health policies and initiatives should
make additional efforts to be better oriented, i.e. better
focused on risks factors and on diseases that caused
most of the health burden. In addition, more efforts have
to be made to define health goals or to focus prevention
actions in at risk groups.
Inequality in health across EU15 should also be further
studied, using for example the SDI index available in the
2016 GBD study.
In 2015, the Belgian government approved a reform
of health care funding and especially of the hospital
funding system. In such a context, future studies need
to monitor the situation and assess the impact of
these changes.
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Conclusion
Even though YLLs due to premature deaths decreased
between 1990 and 2016 in Belgium, Belgium’s ranking
among the EU15 in terms of YLLs and DALYs decreased
from 1990 to 2016. Significant health gains appear pos-
sible by acting on risk factors directly linked to a signifi-
cant part of the Belgian burden of diseases, i.e., alcohol
and tobacco consumption, and high body mass index.
Care management of people with chronic disease or
long-term severe disease sequelae must also receive spe-
cial attention, because they are carrying a heavy burden
in Belgium. National burden of disease estimates can
help defining Belgian health targets and are necessary as
external validity of GBD results is not always
guaranteed.
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